
==== Front
Gastro Hep Adv
Gastro Hep Adv
Gastro Hep Advances
2772-5723
Elsevier

S2772-5723(24)00076-1
10.1016/j.gastha.2024.05.012
Narrative Reviews
The Roles of Gut Microbiota Metabolites in the Occurrence and Development of Colorectal Cancer: Multiple Insights for Potential Clinical Applications
Cheng Wenyue 123
Li Fan 123
Yang Rongcun ryang@nankai.edu.cn
123∗
1 Translational Medicine Institute, Affiliated Tianjin Union Medical Center of Nankai University, Nankai University, Tianjin, China
2 Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin, China
3 State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China
∗ Correspondence: Address correspondence to: Rongcun Yang, MD, PhD, Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin 300071, China. ryang@nankai.edu.cn
07 6 2024
2024
07 6 2024
3 6 855870
20 11 2023
21 5 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Colorectal cancer (CRC) is one of the most common cancers worldwide. The occurrence and development of CRC are related to multiple risk factors such as gut microbiota. Indeed, gut microbiota plays an important role in the different phases of colorectal cancers (CRCs) from oncogenesis to metastasis. Some specific bacteria such as Fusobacterium nucleatum (F. nucleatum) associated with CRCs have been found. However, recently identified bile acid and tryptophan metabolites as well as short chain fatty acids (SCFAs), which are derived from gut microbiota, can also exert effects on the CRCs such as that SCFAs directly inhibit CRC growth. Importantly these metabolites also modulate immune responses to affect CRCs. They not only act as tumor inhibiting factor(s) but also promotor(s) in the occurrence, development, and metastasis of CRCs. While gut microbiota metabolites (GMMs) inhibit immunity against CRCs, some of them also improve immune responses to CRCs. Notably, GMMs also potentially affect the shaping of immune-privileged metastatic niches through direct roles or immune cells such as macrophages and myeloid-derived suppressive cells. These findings offer new insights for clinical application of gut microbiota in precise and personalized treatments of CRCs. Here, we will mainly discuss direct and indirect (via immune cells) effects of GMMs, especially SCFAs, bile acid and tryptophan metabolites on the occurrence, development and metastasis of CRCs.

Keywords

Colorectal Cancer
Gut Microbiota
Immune Cells
Metastasis
Abbreviations used in this paper

3-HAA 3-hydroxyanthranilic acid

5-HT serotonin

AHR ary hydrocarbon receptor

β-cat β-catenin

BA bile acid

Bregs regulatory B cells

CA cholic acid

CD cluster of differentiation

CAD cadaverine

CDCA chenodeoxycholic acid

CoA coenzyme A

COX-2 cyclooxygenase-2

CRC Colorectal cancer

CSC cancer stem cell

CTLA-4 cytotoxic T lymphocyte-associated antigen-4

DCA deoxycholic acid

E-cad E-cadherin

EGFR epidermal growth factor receptor

EMT epithelial-mesenchymal transition

GMM gut microbiota metabolite

GMMs gut microbiota metabolites

GPNMB glycoprotein neuromedin B

GPBAR1 G protein-coupled bile acid receptor 1

H2S hydrogen sulfide

HDAC histone deacetylase

HFD high-fat diet

HGF hepatocyte growth factor

HIF1α hypoxia-inducible factor 1α

IAA idole-3-acid-acetic acid

ICI immune checkpoint inhibitor

IPA indole-3-propionic acid

Kyn kynurenine

LCA lithocholic acid

MDSCs myelod-derived suppressive cells

MDSCs myeloid derived suppressive cells

MMP matrix metalloproteinase

NLRP3 nucleotide oligomerization domain-like receptor 3

NO nitric oxide

PD-1 programmed cell death protein 1

PI3K/AKT phophatidylinsitol-3-kinase/protein kinase B

PXR pregnane X receptor

ROI reactive oxygen intermediates

RORγt retinoid-related orphan receptor γt

ROS reactive oxygen species

SAA3 serum amyloid A3

SCFAs Short chain fatty acids

SNAI1 snail family transcriptional repressor 1

STING stimulator of interferon genes

TAMs tumor-associated macrophages

Teff T effctive cells

TF tissue factor

TGFβ transforming growth factor-β

THDCA taurohyodeoxycholic acid

TLR toll-like receptor

TMAO trimethylamine-N-oxide

Tregs regulatory T cells

Trp tryptophan

TUDCA taurousodeoxycholic acid

uPAR urokinase-type plasminogen activator receptor

VDR vitamin D receptor

VEGF vascular endothelial growth factor
==== Body
pmcIntroduction

Colorectal cancer (CRC) is one of the most common cancers and accounts for approximately 10% of all annually diagnosed cancers.1,2 The occurrence and development of CRC are related to multiple risk factors such as gut microbiota. Indeed, gut microbiota not only plays a critical role in normal gut physiological functions such as digestion, biosynthesis of vitamins, generation of heat, gut immunity, and maintenance of gut homeostasis, but also contributes to a wide range of diseases such as tumor.

The roles of gut microbiota in the occurrence and development of CRCs have been widely reviewed. Multiple factors of gut microbiota such as gut dysbiosis, specific pathogenic microbes, metabolites and virulence factors can contribute to the initiation and progression of CRCs. Although there exist debates surrounding the causal relationship between microbial dysbiosis, which is compositional and functional alterations of the gut microbiome,3 and colorectal tumorigenesis,4 a number of studies have shown that the dysbiosis of gut microbiota is related to CRC development and progression. The characteristic changes in gut microbiota can happen in various CRC stages, including early and advanced CRCs in CRC patients. Recent metagenomic and metabolomic analyses showed distinct gut microbiome-derived phenotypes in early onset of CRCs.5 There were enriched Flavonifractor plauti and increased tryptophan (Trp), bile acid (BA), and choline metabolism, whereas in late-onset CRC, Fusobacterium nucleatum enrichment, short-chain fatty acid depletion, reduced microbial gamma-aminobutyric acid biosynthesis and a shift in acetate/acetaldehyde metabolism towards acetyl-coenzyme A production were found5 Indeed, specific bacteria associated with the onset and progression of CRCs have been found, such as Fusobacterium nucleatum (F. nucleatum), Enterococcus faecalis (E. faecalis), Streptococcus gallolyticus (S. gallolyticus), Bacteroides fragilis (B. fragilis), and Escherichia coli (E. coli). The metabolites from gut microbiota can not only cause initial inflammation but also play an important role in the CRCs from oncogenesis to metastasis. Mechanistically, CRCs can be derived from the metabolites mediated genetic and epigenetic pathways such as histone modifications, DNA methylation, and noncoding RNAs.6 However, gut microbiota can also produce a wide range of anticancer metabolites, including bacteriocins, antibiotics, peptides, enzymes, and toxins to inhibit tumor growth.

Notably, recent studies have shown that gut microbiota metabolites (GMMs) such as short chain fatty acids (SCFAs), BA, and Trp metabolites not only directly influence tumor growth7 but also indirectly affect genetic and epigenetic regulation and the metabolism in the immune cells, including myeloid-derived immune cells such as macrophages (Macs) and myeloid-derived suppressive cells (MDSCs), and lymphoid-derived immune cells such as regulatory T cells (Tregs) and regulatory B cells (Bregs). These immune cells can express the receptors of SCFAs, Trp, and BA metabolites. 8 Their activation may promote the differentiation and alter the functions of immune cells to suppress immune responses to maintain the homeostasis of gut tissues. Notably, gut microbiota mediated immune cells such as immunosuppressive Macs and MDSCs can also assist metastatic dissemination by creating niches which allow tumor colonization. 9 However, some GMMs such as SCFAs, BA, and Trp metabolites can also promote antitumor immune responses. Here, we will mainly discuss the effects of recently identified BA and Trp metabolites as well as SCFAs from gut microbiota on the CRCs or CRC-associated immune cells. These GMMs not only directly inhibit tumor growth but also indirectly promote development of CRCs. Especially, they not only suppress immune responses but also promote immunity against CRCs.

Gut Microbiota and Its Metabolites

SCFAs, BA, and Trp metabolites from gut microbiota not only directly affect CRCs but also indirectly regulate gut and systemic immune response to influence the occurrence, development and metastasis of CRCs.

SCFAs

SCFAs, mainly including acetate, propionate and butyrate, are from dietary fiber fermentation in the cecum and colon by gut bacteria. Acetate can be generated by Akkermansia muciniphila, Bacteroides spp., Blautia hydrogenotrophica, Clostridium spp., Bifidobacterium spp., Prevotella spp., Ruminococcus spp.,and Streptococcus spp.10, 11, 12 Buyrate is produced by Anaerostipes spp., Coprococcus comes, Clostridiales bacterium, Coprococcus eutactus, Coprococcus catus, Costridium symbiosum, Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii, Roseburia insulinivorans and Roseburia intestinalis.11,13,14 Propionate is also generated through Akkermansia muciniphila, Bacteroides spp., Clostridium spp., Coprococcus spp., Dialister spp., Eubacterium spp., Phascolarctobacterium succinatutens, Roseburia spp., Ruminucocus spp., and Veillonella spp.11,13,15

BA Derivatives

Two primary BAs, cholic acid (CA) and chenodeoxycholic acid (CDCA), are generated in the liver. These primary BAs are then conjugated, deconjugated, and transformed into other derivatives in gut microbiota. Bacteria such as Actinobacteria hathewayi, Bacteroides vulgatus, and Lactobcillus (L) ruminis can conjugate glycine to deoxycholic acid (DCA), CDCA, or CA in vitro16 Bacteria Clostridium scindens, Bacterorides vulgatus, L. ruminis, and Holdemania filiformis can also conjugate CDCA, DCA, or CA to one or more amino acids such as alanine, arginine, and aspartate.16 Notably, 4 distinct ways are used to transform BAs, including deconjugation, dehydroxylation, oxidation, and epimerization in human.17 Conjugated BAs may be deconjugated in gut bacteria18 such as Bifidobacterium spp.,19 Bacteroides spp.,20 Clostridium spp.21,22 and Enterococcus spp.,23 and L. spp.24 While BAs are deconjugated, BAs can be converted into secondary BAs, ie, DCA and lithocholic acid (LCA) through bacterial BA hydrolases25 and dehydroxylases26 to remove 7α or 7β-hydroxyl groups from primary BAs in the large bowel27 A range of oxo-, epi- and iso-derivatives such as 3-oxoLCA, 7-oxoCDCA, 12-oxoCA, 7-oxoCA, 12-oxoDCA, iso-LCA, 3-oxo-LCA, 3-oxoallo-LCA, isoalloLCA, allo-LCA, and 3-ketoLCA are also found in gut bacteria17,28,29 such as Adlercreutzia, Bifidobacterium, Clostridium, Collinsella, Enterocloster, Eggerthella, Gordonibacter, Peptoniphilus, Phocea, Monoglobus, Raoultibacter, and Mediterraneibacter, and also Clostridium absonum, Collinsella aerofaciens, Stenotrophomonas maltophilia, and Ruminococcus gnavus30,31 7α-epimerization to ursodeoxycholic acid (UDCA) also occurs in Clostridium baratii17 However, the exact gut bacterium species to produce these BA metabolites need to be further identified.

Trp Metabolites

Trp metabolites are generated by gut bacteria such as indole by Bacteroides ovatus, Clostridium limosum, Enterococcus faecalis, and E. coli32; Indole-3-acid-acetic (IAA) and indole-3-propionic acid (IPA) by Bifidobacterium spp. and Clostridium bartlettii, and Clostridium sporogenes33, 34, 35; Indoleacrylic acid and IPA by Peptostreptococcus spp36; Indole-3-aldehyde by L. johnsonii, L. reuteri, L. acidophilus, and L. murinus37; Skatole by Bacteroides spp. and Clostridium spp35,38; and tryptamine by Clostridium sporogenes and Ruminococcus gnavus [50]. In addition, Bacillus, Burkholderia, Pseudomonas, Stenotrophomonas, Xanthomonas, and Shewanella also encode enzymes homologous to those of the eukaryotic kynurenine (Kyn) pathway to produce Kyn and downstream metabolites such as 3-hydroxyanthranilic acid (3-HAA).39

In addition, inosine is a purine metabolite of Akkermansia muciniphila and Bifidobacetrium pseudolongum.40 It is also produced by Bacillus subtilis, Corynebacterium ammoniagenes, and E. coli. Hydrogen sulfide (H2S) is generated by sulfur-metabolizing bacteria such as Desulfovibrio spp. These bacteria can metabolize taurine (Bilophila wadsworthia) or cysteine (Fusobacterium nucleatum) to form H2S.41

The Roles of GMMs in CRCs

GMMs such as SCFAs, BA, and Trp metabolites from bacteria not only directly inhibit but also promote the occurrence and development of CRCs (Figure 1).Figure 1 Suppression or promotion on CRCs by GMMs. BAs such as GCA, TCDCA, TCA, GCDCA, GCDCA and TDCA, and secondary BAs such as DCA generated by bacteria can promote colorectal cancer growth; 5-HT and 3-HAA from bacteria also promote colorectal cancer growth; Colorectal cancer growth can be promoted by H2S, TMAO, SLPI, and bacteria toxins such as adhesin A and colibactin derived from bacteria. Notably, GMMs such as UDCA, LCA, kynurenic acid, 8-hydroxyquinaldic acid, UroA, IsoUroA, succinic acid, inosine, acetate, propionate and butyrate generated by bacteria can also inhibit colorectal cancer. 3-HAA, 3-hydroxyanthranilic acid; 5-HT, 5-hydroxytryptamine; BAs, bile acids; CRC, colorectal cancer; DCA, deoxycholic acid; GCA, glycocholic acid; GCDCA, glycoanthropodeoxycholic acid; GCDCA, glycodeoxycholic acid; GMM, gut microbiota metabolite; H2S, hydrogen sulfide; LCA, lithocholic acid; SLPI, secretory leukocyte protease inhibitor; TCA, taurine-conjugated cholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TMAO, trimethylamine N-Oxide; UDCA, ursodeoxycholate.

Inhibition on CRCS by GMMs

Gut microbiota-derived peptides, bacterial toxin, bacteriocins, bacterial enzymes, and antibiotics are directly against cancer. However, recent studies found that SCFAs, BA, and Trp metabolites from gut microbiota can also inhibit CRCs.

SCFAs

Studies have shown that lower fecal concentrations of 3 major SCFAs (acetate, butyrate, and propionate) are associated with higher risk of CRCs and incidence of CRCs. A significantly lower abundance of SCFAs and SCFA-producing bacteria has also been demonstrated in the CRCs. These SCFAs may enter colonic intestinal cells through passive diffusion, counter-transport with bicarbonate, monocarboxylic acid transporter 1, and sodium-coupled monocarboxylic acid transporter-1.42 They have exhibited protective actions against colon carcinogenesis. The inhibitory mechanism shows a close association with the inhibition of histone deacetylases (HDACs). The transformation of glycolytic metabolism is a dominant characteristic of carcinoma cells.43 Colorectal cells prefer glucose to butyrate as their preferred energy resource due to Warburg effect pathway. Butyrate not only can enter the nucleus directly to inhibit HDAC but also cause a reduction in short-chain acyl-CoA dehydrogenase levels, which are the primary process in the catalyzation of mitochondrial butyrate oxidation.44 This process reduces the auto-oxidation of butyrate in CRC cells to cause accumulation of butyrate in carcinoma cells, thereby restraining CRC development.45 SCFAs also inhibit the Wnt/β-catenin signaling pathway by inhibiting HDAC activity, thereby preventing the development of intestinal tumors in a murine model.46 Butyrate as a HDAC inhibitor also participates in the apoptosis of CRC cells.47 Notably, butyrate can protect from intestinal tumor growth by blocking the activation of calcineurin and nuclear factor of activated T cells C3 in mouse and human.48 Interestingly, sodium butyrate could induce ferroptosis in CRC cells through cluster of differentiation (CD)44/secondary lymphoid tissue chemokine 7A11 signaling pathway.49 Tributyrin alleviated gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated mice.50 Acetate also inhibited CRC cell multiplication and triggered CRC cell apoptosis in a dose-dependent manner. These effects of acetate were mediated via suppression of the phosphatidylinositol-3-kinase/protein kinase B (PI3K/protein kinase B) pathway.51

BA metabolites

The UDCA, a secondary BA, which has a chemical structure with DCA but unlike DCA, has been demonstrated to inhibit CRC occurrence. While patients with CRCs take UDCA for a long period of time, these patients are less likely to relapse following the removal of the colorectal adenoma. Clinical metagenomic and metabolomic studies have also revealed links between microbial BA metabolism and inflammatory bowal disease and CRC progression.52 Serum concentrations of BAs, particularly downstream microbial metabolites of CA, were strongly associated with increased risk of CRC among women.52 Notably, decreasing concentration of hydrophobic BA and increasing hydrophilicity of the bile pool were involved in the suppression of UDCA on CRCs.53,54 UDCA also protected against malignant progression of CRC through TGR5–yes-associated protein.55 In addition, LCA had antiproliferative action on different cancer cell lines.56

Trp metabolites

Alteration of fecal Trp metabolism mediated by microbiota is involved in the pathogenesis of CRCs. Indeed, higher levels of plasma Trp were associated with lower CRC risk57; whereas increased serotonin, a metabolite of Trp, was related to a higher risk of CRCs. The Kyn-to-Trp ratio was also positively associated with CRCs.58 Supplementation with L. reuteri, which produces Trp metabolites, inhibits SREBP2 expression and tumorigenesis in mice with gut flora disequilibrium. In addition, kynurenic acid, a Trp metabolite, could inhibit proliferation of several cancer cell lines including CRCs.59 8-hydroxyquinaldic acid, another Trp metabolite inhibited migration of CRC cell lines colorectal cancer cell line and LS-180 and increased the expression of β-catenin and E-cadherin. The Trp metabolism also was effective in inducing the differentiation of Tregs.

Others

Other GMMs are also associated with tumor growth such as that inosine, a purine metabolite of A. muciniphila and B. pseudolongum is effective in controlling cell growth and tumor evolution.60 Ellagitannins and ellagic acid are dietary polyphenols, which are poorly absorbed but extensively metabolized by the human gut microbiota to produce different urolithins (Uros). Produced UroA and isoUroA can induce apoptosis in colorectal tumor cell line caco-2 cells through arresting in S and G2/M phases of cell cycle. Kasimsetty et al61 also confirm the time- and dose-dependent anticlonogenic and proliferative activity of UroA in human CRC cells (HT-29) through cell-cycle arrest in the G0/G1 and G2/M stages and apoptosis induction. In addition, F. nucleatum-derived succinic acid also induced tumor resistance to immunotherapy in CRCs.

Promotion on CRCs by GMMs

There is a matter of debate in a causal relationship between gut microbiota and colorectal tumorigenesis. However, studies have shown that the dysbiosis of gut microbiota is related to CRCs. Specific gut bacteria, such as Fusobacterium nucleatum, Escherichia coli, and Bacteroides fragilis could be involved in colorectal carcinogenesis. These bacteria produce metabolites, such as H2S, trimethylamine-N-oxide (TMAO), which are likely to promote inflammation and subsequently cancer development.62 Previous reports also showed that bacterial toxins such as toxin from B. fragilis, adhesin A from F. nucleatum and colibactin from E. coli6,63 can promote the occurrence and development of CRCs. They participate in metabolism of dietary components to produce tumorigenic metabolites, interaction with genetic or epigenetic alterations, induction of inflammation and the recruitment of immunosuppressive cells. Indeed, colibactin could cause the breakage of double-strand DNA, chromosome instability, and cell senescence in eukaryotic cells.64 Notably, the gut microbiota also interacted with certain environmental factors such as a high-fat diet (HFD)65 and cigarette smoking66 to promote the development of CRCs. The fat-mediated alterations of the gut microbiota linked BA metabolism to CRC risk and colonic tumorigenesis.67 Cigarette smoke also promoted CRC through modulation of gut microbiota and related metabolites.66 However, recent studies have also found that GMMs such as secondary BAs and Trp metabolites are related to the promotion on CRCs.

BA metabolites

The secondary BAs have exhibited procarcinogenic properties. Paired microbiome and metabolome analyses were associated with BA changes with CRC progression. The plasma levels of 7 conjugated BA metabolites, including glycocholic acid, taurine-conjugated CA, glycodeoxycholic acid, taurochenodeoxycholic acid, and taurodeoxycholic acid (TDCA) were positively correlated with risk of colon cancer. Metabolomic analysis showed increased BA metabolite TDCA in the colon of smoke-exposed mice66 and in the colon of individuals consuming HFDs, which were associated with an increased risk of CRCs. HFDs also promoted colorectal tumorigenesis through modulating gut microbiota and metabolites.65 HFD feeding could increase CRC growth in β2AR-dependent manner.68 Interestingly, germ-free mice transplanted with stools from smoke-exposed mice had increased colonocyte proliferation.66 Cigarette smoke could promote CRC through modulation of gut microbiota and related metabolites.66 The secondary BAs fed mice also increased inflammation and induced CRCs.69 Studies found that hydrophobic BAs can produce reactive oxygen species (ROS) and reactive nitrogen substances, which cause oxidative stress, damage to DNA and proteins, and destruction of the base excision repair pathway. In the carcinogenic methane peroxide-induced tumor model system, DCA raises the rate of CRCs in Kirsten rat sarcoma viral oncogene homolog point mutual mutations. DCA can also enhance the local spatial aggregation of phospholipid acid and induces co-localization between phospholipid acid and epidermal growth factor receptor (EGFR) to promote EGFR dimerization/oligomerization and EGFR-MARK signaling. EGFR, as a tyrosine kinase receptor can promote proliferation, invasion or metastasis of CRCs by mutation or overexpression. Notably, unconjugated BAs and tertiary BAs are not associated with cancer risk.

Trp metabolites

Trp metabolites serotonin (5-HT) and 3-hydroxyanthranilic acid (3-HAA) can facilitate tumor cells such as CRCs to escape from ferroptosis. Mechanistically, both 5-HT and 3-HAA were as potent radical trapping antioxidants to eliminate lipid peroxidation, thereby suppressing ferroptotic cell death.70 During this process, monoamine oxidase A markedly abrogated the protective effect of 5-HT via degrading 5-HT. Kynureninase, which was essential for 3-HAA production to confer cells resistant to ferroptotic cell death, whereas 3-hydroxyanthranilate 3,4-dioxygenase significantly blocked 3-HAA mediated ferroptosis inhibition.70 3-IAA, a Trp metabolite can induce a downregulation of the ROS-degrading enzymes glutathione peroxidase 3 and glutathione peroxidase 7 to reduce tumor proliferation.71 Probiotic L. reuteri promotes interferon-γ-producing CD8 T cells, thereby bolstering immune checkpoint inhibitor (ICI) via its released dietary Trp catabolite I3A.72

Others

TMAO engaged in a number of genetic pathways has an apparent association to carcinomas, particularly colon cancer. Mechanistically, TMAO can potentially cause CRC by inflammation, DNA damage, oxidative stress, and protein misfolding.73 However, it remains uncertain whether elevated TMAO levels are a reason or a result of cancer. The level of H2S in the feces of CRC subjects is higher than in the control group without tumors.74 H2S promotes the proliferation of CRCs via promoting the phosphorylation of Please add expansions for protein kinase B, secondary lymphoid tissue chemokine, CD, inflammatory bowal disease, TGR, HT, Kirsten rat sarcoma viral oncogene homolog, extracellular regulated protein kinase, interluekine, G protein-coupled bile acid receptor 1 (GPBAR1), GATA, PD-L, CRCS and extracellular regulated protein kinase in vitro. In addition, microbiota-derived genotoxin tilimycin also caused colonic stem cell mutations. Urea cycle activation triggered by host-microbiota maladaptation could drive colorectal tumorigenesis. Dietary iron also modulated gut microbiota and induced secretory leukocyte protese inhibitor secretion to promote colorectal tumorigenesis.

Effects of GMMs Associated Immune Cells on the CRCs

GMMs play a critical role in maintaining homeostasis of gut and systemic immunity; however, they also promote immune responses against CRCs (Figure 2). Within CRC microenvironment, there are multiple antitumor immune cells, including multiple kinds of immune cells such as effective CD8 cells, CD4 Th1 cells, Th17 cells, natural killer (NK) cells, dendritic cells (DCs) and inflammatory Macs; whereas other immune cells such as MDSCs, immunosuppressive Macs (M2-like Macs) and N2 neutrophils, Tregs and Bregs can contribute to tumor growth. These tumor-associated immune cells can be regulated by GMMs. Notably, these GMM-mediated immune cells also produce effects on the tumor environments such as that Treg cells in tumor environment can produce vascular endothelial growth factor (VEGF) to promote angiogenesis, and inhibit T effective (Teff) cells, NK cells and antigen-presenting cells by inhibitory cytokines such as IL-10 and cytotoxic molecules such as granzymes and perforin, which can directly kill Teff cells and antigen-presenting cells.75Figure 2 Suppression or promotion on CRCs by GMM-associated immune cells. SCFAs promote colorectal cancer growth through downregulating Mac and upregulating M2. Notably, SCFA butyrate promotes colorectal cancer through upregulating Treg and Breg, and downregulating Th1, Th22 and Th17; Colorectal cancer is also promoted through acetate downregulating Th17; However, SCFAs also inhibit colorectal cancer through T cells. BA metabolites promote colorectal cancer through upregulating M2 and MDSC and downregulating Th2 and Th1; Whereas BA metabolite CDCA also inhibits colorectal cancer through downregulating M2. Trp metabolites promote tumor growth through downregulating Th1, Mac, NK and CD8. Notably, Trp metabolites IPA and Kyn, 3-HAA and indole-3-carbinol as well as IAA promote tumor growth through downregulating Th17 and upregulating Treg and Breg respectively; However, Trp metabolites ILA and KYNA also inhibit tumor through upregulating CD8 and Th17; Other GMM such as Urolithin A promote colorectal cancer; Whereas inosine, STING, TMAO, PSA and anacardic acid can inhibit colorectal cancer through upregulating Th1, M1, and CD8. 3-HAA, 3-hydroxyanthranilic acid; 3-oxoLCA, 3-oxo-lithocholic acid; 5-HIAA, 5-hydroxyindole-3-acetic acid; BA, bile acid; Breg, regulatory B cells; CDCA, chenodeoxycholic acid; CRC, colorectal cancer; GMM, gut microbiota metabolite; IAA, indole-3-acetic acid; ILA, indole-3-lactic acid; IPA, indole-3-propionic acid; IsoalloLCA, isoallo-lithocholic acid; KYN, kynurenine; KYNA, kynurenic acid; L. plantarum, Lactobcillus plantarum; LCA-3-S, sulfate of LCA; M1, M1 macrophages; M2, M2 macrophages; Mac., macrophages; MDSC, myeloid-derived suppressive cells; NK, natural killer cells; PSA, polysaccharide; SCFAs, short chain fatty acids; Th, T helper; Treg, regulatory T cells; Tr1, T regulatory cells; Trp, tryptophan; THDCA, taurohyodeoxycholic acid; STING, stimulator of interferon genes; TMAO, trimethylamine N-Oxide.

Suppression on Immunity Against CRCs by GMMs

SCFAs

SCFAs have an important role in maintaining immune homeostasis through their receptors such as G-protein coupled receptor (GPR)43. Nucleotide oligomerization domain–like receptor thermal protein domain associated protein 3 (nucleotide oligomerization domain–like receptor 3 (NLRP3))–mediated inflammatory signaling pathways could be negatively regulated by SCFAs to inhibit the activation of Macs. SCFAs also triggered autophagy in cancer cells to promote M2 polarization in Macs, accelerating tumor advancement. Notably, under Treg cell polarization condition, SCFAs could promote the conversion of naïve T cells toward Tregs.76, 77, 78 SCFA butyrate also suppressed Th17-associated retinoid-related orphan receptor γt (RORγt) and increased the expression of Treg-associated Foxp3.79 DCs exposed to butyrate facilitated the differentiation of naïve T cells into Foxp3+Tregs.80 Administration of SCFAs also increased the Bregs (B regulatory cells) frequency.81 In addition, gut microbiota SCFAs also affected immune effective cells such as that butyrate could decrease the proliferation and cytokine production in Th1, Th17, and Th22 cells.82

BA metabolites

BA metabolites have widely effects on immune cells through receptors such as TGR5 (GPBAR1), farnesol-X-receptor, vitamin D receptor (VDR), liver X receptor, pregnane X receptor (PXR), and RORγt. They are essential to maintain tolerant phenotypes of the Macs via TGR5 (GPBAR1). Secondary BAs DCA and LCA could act as endogenous inhibitors of NLRP3 activation by activating TGR583 or TGR5-cAMP(adenosine monophosphate)-dependent ubiquitination of NLRP384 farnesol-X-receptor, another BA receptor, is an important negative regulator of NLRP3.84 BA metabolites could also disrupt intracellular calcium homeostasis, which is essential for nuclear factor of activated T cells signaling and T cells activation.85 24- NorUDCA, a BA metabolite, reshaped immunometabolism in CD8+ T cells,86 which affected lympho-blastogenesis, expansion, glycolysis and target of rapamycin complex 1 (mTORC1) signaling. Notably, the physiological concentrations of unconjugated LCA could inhibit the activation of primary human and mouse CD4+ Th1 cells through a VDR-dependent mechanism, resulting in decreased tumor necrosis factor-α and IFN-γ.87 VDR activation also promoted a shift from Th1 to Th2 phenotype through increased production of the transcription factors c-Maf and GATA-3.88 Increased number of tumor-infiltrating Treg cells is associated with poor prognosis in various cancer types.89 Notably, BA metabolites such as 3-oxoLCA, isoalloLCA, and isoDCA have been identified as the regulators of Treg cells by inhibiting the differentiation of Th17 cells and increasing the differentiation of Treg cells in colon. NR4A1 (Nuclear receptor subfamily 4 group A member 1) was also required for the role of isoalloLCA in Treg cells.90 IsoalloLCA could increase binding of NR4A1 at the Foxp3 locus to enhance Foxp3 gene transcription. The differentiation of Th17 cells was also inhibited by 3-oxoLCA by RORγt,91 which finally affected the Th17/Treg balance. The sulfate of LCA (LCA-3-S) selectively suppressed Th17 cell differentiation without influence on Th1, Th2, and Treg cells.92 Taurohyodeoxycholic acid, a natural 6α-hydroxylated BA, not only reduced the secretion of Th1/Th17-related cytokines and transcription factors, but also increased the production of Th2/Treg-related cytokines and the expressions of transcription factors in the colon.93 In addition, the BA derivative TDCA also increased MDSCs in the spleen of septic mice.94 MDSCs, as immunosuppressive cells antagonized the activities of T cells by depleting amino acids, and expressing transforming growth factor beta (TGFβ) and PD-L1.95 Notably, intratumoral enrichment of F. nucleatum in patients with CRC was associated with enrichment of MDSCs.96 Taurodeoxycholic acid (TDCA) also increased the number of MDSCs in the spleen of septic mice.94

Trp metabolites

Trp metabolites have an important role in the differentiation and function of immune regulatory cells through their receptors such as ary hydrocarbon receptor (AHR). Administration of AHR ligand indole-3-carbinol, a Trp metabolite, was sufficient to restore Treg compartment.97 Notably, in vitro experiments also verified that Trp metabolites IPA inhibited the differentiation of Th17 cells and promoted the differentiation of Treg cells.98 Notably, during T regulatory 1 (Tr1) cell differentiation, AHR could be physically associated with c-Maf to activate immunosuppressive cytokines IL-10 and IL-21 promoters.99,100 Differentiation and function of IL-10-producing CD19+CD21hiCD24hiBregs were also regulated by AHR.101 Trp metabolite IAA from gut microbiota together with LPS could activate transcription factor PXR and nuclear factor-κB to induce the generation of IL-35+ Breg cells.102 In addition, Kyn from gut microbiota could enhance differentiation of Tregs through the activation of AHR.103, 104, 105, 106, 107, 108 3-HAA, a downstream metabolite of Kyn promoted the generation of Foxp3+Treg cells and immunosuppressive TGF-β in a nuclear coactivator 7 (NCOA7)-dependent pathway.109 Microbiota-derived Trp catabolites mediated the chemopreventive effects of statins on CRC by inhibiting Th 17 cell differentiation by targeting the nuclear receptor, retinoic acid receptor-related orphan receptor γt (RORγt).110 Notably, Trp metabolites could also activate AHR in tumor-associated Macs to suppress antitumor immunity111 such as that the metabolites of dietary Trp generated by the gut microbiota activated the AHR in myeloid cells, promoting an immune suppressive tumor microenvironment.112 In addition, Trp metabolites were also involved in the regulation of immune effective cells. programmed cell death protein-1 (PD-1), an immunosuppressive molecule in CD8+T cells could be upregulated through AHR.113 3-HAA metabolite of Kyn could induce apoptosis of T-cells.114 L-kyn metabolites also caused NK cell death via ROS pathway.115

Others

Gut microbiota urolithin A alleviated colitis in mice by improving gut microbiota dysbiosis, modulating microbial Trp metabolism, and triggering AHR activation.116 Urea from Bifidobacterium, could enter into Macs to inhibit the binding efficiency of p-signal transucer and activator of transcription 1 to promotor region, and further skew Macs toward a protumor phenotype characterized by the accumulation of polyamines.117

Promotion on Immunity Against CRCs by GMMs

SCFAs

There are contradictions about the effects of SCFAs on the immune cells. Besides, SCFAs play an important role in maintaining homeostasis, SCFAs also increase tumor-killing CD8+ T cells and reduce immune-suppressing Tregs in tumor tissues such as that the supplements using SCFAs or SCFA-producing bacteria increase intratumor T cells and raise the concentration of cytokines interferon-γ and tumor necrosis factor-α to result in inhibition of tumor growth.118 Decreased abundance of SCFA-producing taxa such as Coprococcus was subsequently associated with a lower number of intratumoral CD4+ and CD8+cells and peripheral CD4+ T cells. He et al demonstrated that butyrate could promote the antitumor activity of intratumoral and draining lymph node CD8+ T cells in an IL-12 signaling pathway-dependent manner in a mouse model.119 Thus, SCFAs have beneficial effects in CRCs.

BA metabolites

BA metabolite CDCA suppressed M2 Mac polarization.120 Mechanistically, it could cause mitochondrial morphology damage, including swelling and reduction of cristae, decreased mitochondrial membrane potential, and elevated mitochondrial calcium level, which resulted in the production of ROS.

Trp metabolites

L. plantarum–derived indole-3-lactic acid, a Trp metabolite, could ameliorate colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity. Interventions with L. reuteri or its metabolite indole-3-lactic acid could complement chemoprevention strategies for CRCs.110 Kynurenic acid also modulated the recruitment and aggregation of GPR35-positive Macs to cause a robust Th17 immune response.

Others

Both A. muciniphila and L. rhamnosus activated stimulator of interferon genes–interferon pathways to slow tumor progression. Bifidobacterium, another kind of bacteria, altered the functional capacity of DCs to induce CD8+T cell proliferation and IFNγ production.121,122 It also promoted Th1 transcriptional differentiation and antitumor immune responses to improve immunocheckpoint blockage efficacy.40 Bacteroides fragilis induced Mac polarization to M1 and upregulated CD80 and CD86 expression on the cells, which could promote innate immunity.123 Enterococcus hirae was able to induce the polarization of immune cells in secondary lymphoid organs towards a Th1 IFNγ phenotype, leading to increased ratios of cytotoxic T cells to Tregs in mouse models. Eleven strains combined with immunocheckpoint blockages robustly induced IFN γ+CD8+T cells to inhibit tumor growth. Faecalibacterium increased CD4+T cell proportion and also reduced Treg cell proportion in peripheral blood. L. plantarum effectively increased expression of the natural cytotoxic receptors, and promoted NK cell activation to trigger innate immunity.

Effects of GMMs on the Formation of CRC Metastasis

Potential Effects of GMM-Mediated Tumor-Associated Macs (TAMs) and MDSCs on CRC Metastasis

There are many factors that regulate the dissemination and distant organ colonization of CRC cells, including genetic mutations, metastasis-initiating cells, epithelial-mesenchymal transition (EMT), and the tumor microenvironment. The GMMs induced immunosuppressive cells such as TAMs and MDSCs can help direct metastatic dissemination by creating a niche which allow tumor colonization. These immunosuppressive cells can achieve protumor functions by generating a proinflammatory cytokines, maintaining an immunosuppressive microenvironment, remodeling the matrix and creating a proangiogenic and proinvasive environment, and secreting growth factors (Figure 3).Figure 3 Effects of GMMs on CRC metastasis via Macs and MDSCs. TAMs and MDSCs promote the formation of metastatic tumor. SCFAs, BA, and Trp metabolites can promote colorectal cancer metastasis through causing tumor cell arrest by MDSC derived IL-1β, CCL9 and TF, and promoting tumor neoangiogenesis and vascular permeability by IL-1β, FGF2, VEGF, MMPs, SAA3, S100A8, Bv8 and exosomes from MDSCs; SCFAs, BA, and Trp metabolites also promote colorectal cancer metastasis through improving tumor growth by growth factors and cancer stem cells by GPNMB, IL-6, and HGF, causing metastatic niche by IL-1 and genetic instability by NO and ROI, leading to tissue remodeling by TGFβ and proteases, and angiogenesis by IL-1, VEGF and chemokines from TAMs. BA, bile acid; CCL9, C-C motif chemokine 9 protein; CRC, colorectal cancer; DCs, dendritic cells; EGF, epidermal growth factor; GMM, gut microbiota metabolite; GPNMB, glycoprotein neuromedin B; HGF, hepatocyte growth factor; MDSC, myeloid-derived suppressive cells; NK, natural killer cells; NO, nitric oxide; ROI, reactive oxygen intermediates; MMP, matrix metalloproteinase; SAA3, serum amyloid A3; SCFAs, short chain fatty acids; Treg, regulatory T cells; TAMs, tumor-associated macrophages; TF, tissue factor; TGFβ,transforming growth factor-β;Trp, tryptophan; VEGF, vascular endothelial growth factor.

For example, GMM-mediated immunosuppressive Macs could release nitric oxide and reactive oxygen intermediates to cause genetic instability during the initiation phase. These Macs also produced epidermal growth factor and mediators such as IL-6, hepatocyte growth factor, and glycoprotein neuromedin B to promote cancer stem cell expansion. These Macs also potentially contributed to metastatic spread by releasing IL-1 and TGFβ, which could be involved in extracellular matrix (ECM) remodel and pathological fibrosis at later stages. In addition, these Macs also are a critical source of angiogenic factors such as VEGF and proangiogenic chemokines.

Gut microbiota associated MDSCs are also indispensable for the formation of pre-metastatic niche, which promote the niche to favor tumor cell colonization and promote metastasis.124 Indeed, Peptostreptococcus anaerobius induced chronic inflammation and modulated tumor microenvironment by recruiting MDSCs, TANs (Tumor associated neutrophils) and TAMs.125 F. nucleatum also caused liver metastasis by modulating liver microenvironment with accumulation of MDSCs, and reduction of NK and Th17 cells. Thus, host microbiota metabolites mediated immunosuppressive cells could promote CRC metastasis. Recent studies have shown that tumor-associated neutrophils (TANs), which can be polarized to antitumorigenic N1 and protumorigenic N2 phenotype, can form web-like structures known as neutrophil extracellular traps (NETs) both in primary tumor microenvironment and metastatic sites. Interestingly, NETs were involved in cancer progression and metastasis.126 N2 neutrophils support edtumor growth by expressing arginase, metalloproteinase 9 (MMP-9), VEGF, CCL2, CCL5 and CXCL4.126

Direct Roles of GMMs in CRC Metastasis

Tumor metastatic formation from primary tumor to metastatic tumor would pass several stages, including hybrid intermediate cells, transient fetal/regenerative progenitors, differentiated stem cell-like MIC (metastasis initiating cell), dormant MIC and proliferative MIC. Studies have found that some bacteria are involved in the induction of metastasis in primary CRC. They include Fusobacterium nucleatum, Enterococcus faecalis, Bacteroides fragilis, E. coli and Salmonella enterica. Pathogen E. coli upregulated cathepsin K (CTSK) expression which served as a vital mediator between the imbalance of intestinal microbiota and CRC metastasis.127 Gut microbiota-stimulated cathepsin K could mediate Toll-like receptor 4 (TLR4)–dependent M2 Mac polarization and promote tumor metastasis in CRC.127 Some gut microbiota derived metabolites such as LPS has been found to promote EMT through the upregulation of TGFβ-1 and the activation of nuclear factor-κB.128 Clostridium butyricum inhibited EMT of intestinal carcinogenesis through downregulating methyltransferase.129 In addition, cadaverine could inhibit EMT in breast cancer cell lines through modulating the expression of MMP-9. However, studies have shown that SCFAs, BA, and Trp metabolites from gut microbiota also directly affect the shaping of tumor metastasis (Figure 4).Figure 4 Effects of GMMs on tumor metastasis. Tumor metastatic formation from primary tumor to metastatic tumor includes tumor metastatic formation and angiogenesis. They can be affected by SCFAs, BA and Trp metabolites, and other metabolites. SCFA acetate promotes this process through SNAl1, whereas butyrate inhibits this process through Warburg effect; BA metabolites CDCA, UDCA, TUDCA, and LCA can promote metastasis of tumor through upregulating COX-2, PGE2, MMP7/13 and uPAR respectively. Trp metabolites also promote metastasis of tumor through PXR and AHR, whereas metastasis can be inhibited by cytoguardin through downregulating E-cad and upregulating N-cad and Vim. 8-hydroxyquinaldic acid also inhibits metastasis through downregulating β-cat and E-cad. Other metabolites such as that LPS promotes metastasis through upregulating TGFβ1; Whereas CAD can inhibit metastasis through downregulating MMP9. Angiogenesis play an important role in tumor metastatic formation. SCFAs can inhibit the angiogenesis by downregulating VEGF and HIF1α. Notably, angiogenesis can be promoted by BA metabolites CDCA and LCA through upregulating HIF1α and IL-8 respectively, whereas DCA-heparin conjugate inhibits angiogenesis through upregulating βFGF. LPS also promotes angiogenesis by upregulating VEGF. β-FGF, β fibroblast growth factor; AHR, ary hydrocarbon receptor; BA, bile acid; CAD, cadaverine; COX-2, cyclooxygenase-2; CSC, cancer stem cell; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; E-cad, E-cadherin; GMM, gut microbiota metabolite; HIF1α, hypoxia-inducible factor 1α; LCA, lithocholic acid; LPS, lipopolysaccharide; MIC, metastasis initiating cell; MMP, matrix metalloproteinase; N-cad, N-cadherin; PGE2, prostaglandin E2; PXR, pregnane X receptor; SNAI1, snail family transcriptional repressor 1; SCFAs, short chain fatty acids; TGFβ, transforming growth factor β; Trp., tryptophan; β-cat,β-catenin; TUDCA, taurousodeoxycholic acid; UDCA, ursodeoxycholic acid; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; Vim, vimentin.

SCFAs

SCFA butyrate impeded the angiogenesis, metastasis, and survival of CRC cells by inhibiting Sp1 transactivation via the neuropilin-1/VEGF pathway.47 It also reduced clone formation, and migration through the extracellular regulated protein kinase2/mitogen-activated protein kinase pathway. Importantly, butyrate could stimulate the proliferation of normal colonocytes and cancerous colonocytes when the Warburg effect was prevented from occurring.47 However, SCFA acetate could promote metastasis by increasing zinc finger protein snail family transcriptional repressor 1 and acyl-CoA synthetase short chain family member 2 in renal carcinoma cells under glucose limitation.130

BA metabolites

BAs not only participate in the metastatic colonization but also angiogenesis (Figure 4). Differential BA signals emitted by various BA profiles exert distinct pathophysiological traits to the occurrence and development of CRCs. The conjugated BAs promoted CRC-associated liver metastasis. BA metabolite DCA induced EMT and activated VEGF receptor 2.131 DCA, as a transcriptional activator in cancer was associated with the enzyme cyclooxygenase 2 in fibroblasts,132 which had an influence on tumor microenvironment by increasing the invasiveness and proliferation of cancerous cells. In addition, LCA also contributed to cancer progression and metastasis through inducing the expression of urokinase-type plasminogen activator receptor,133 and increasing the expression of matrix MMP genes, including MMP-1, MMP-2, and MMP-7.134 Meanwhile, LCA could promote IL-8 expression to stimulate CRC angiogenesis. In addition, taurousodeoxycholic acid, a conjugated form of UDCA, had anti-invasive impacts through decreased expression of MMP-7 and MMP-13 in metastatic breast cancer.135 UDCA also decreased the invasiveness of gastric carcinoma cells by interfering with the generation of prostaglandin E2.

Trp metabolites

AHR was involved in cancer initiation and metastasis. Trp metabolites, as AHR ligands, participated in the occurrence and development of cancer.37 Indeed, D-kyn could promotes epithelial-to-mesenchymal transition via activating AHR.136 PXR, another receptor of Trp metabolites, also affected cancer growth, progression, and chemoresistance by regulating the expression of genes implicated in proliferation, metastasis, apoptosis, inflammation, and oxidative stress. Notably, cytoguardin, a Trp metabolite, could resist against cancer growth and metastasis.137 8-hydroxyquinaldic acid, another Trp metabolite, also exerted antiproliferative and antimigratory effects on CRCs.138

Gut Microbiota Elicits CRC-Promoting Inflammation

Inflammation is a risk factor and also a hall marker of CRCs. Colonization with the bacteria such as F. nucleatum and B. fragilis was associated with colonic inflammation, which was the principal mechanism in promoting colorectal tumorigenesis.63,139 F. nucleatum could drive a proinflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression in Apcmin/+ mice.140 The FadA adhesin/invasin conserved in F. nucleatum is a key virulence factor. B. fragilis could cause a series of inflammatory reactions due to B. fragilis toxin. Others such as TLR2 and TLR4 (TLR2/4) also sense extracellular microbial products, lipopolysaccharide or lipoteichoic acids from Gram-negative and Gram-positive bacteria, activate TLR2/4 signaling to cause downstream expression of proinflammatory cytokines. The nonspecific immunity activation by peptidoglycan involves immunomodulation by different pattern recognition receptors including peptidoglycan recognition proteins, NLRs, TLRs, and C-type lectin receptors. The inflammasomes such as NLRP3 (a central adenosine triphosphatase (ATPase) domain-leucine-rich repeat-pyrin domain-containing proteins 3) also sense pathogen-associated molecular pattern molecules and damage-associated molecular patterns to leads to secretion of IL-1β and IL-18. Recent studies have shown that SCFAs, BA, and Trp metabolites also promote inflammation through immune cells. Indeed, although it has been widely reported that SCFAs play anti-inflammatory roles through different signaling pathways, SCFAs also play proinflammatory roles through G-protein-coupled receptors. For example, Kim et al141 found that SCFAs activated GPR41 and GPR43 on intestinal epithelial cells to protect immunity and tissue inflammation in C57BL6 mice without free fatty acid receptor 2 or 3 receptors. The impact of BAs on the inflammatory response was investigated in vitro using Caco-2 cells stimulated by IL-1β. These studies showed that secondary BAs exerted anti-inflammatory effects, but sulfation of secondary BAs abolished their anti-inflammatory properties.142 Thus, gut microbiota-elicited inflammation, at least in part, contributes to both the occurrence and development of CRCs.

Modulation of anti-CRC Immunity by Gut Microbiota

Tumor immunotherapies such as ICIs are effective strategies against tumor. The interactions between gut microbiota and cancer immune responses cause the possibility that gut microbiota can affect tumor immunotherapy. Although there are very few reports on gut microbiota-based methods to enhance immunotherapy efficacy in patients with CRCs, specific bacterial species associated with immunotherapy responses in animal models such as Bifidobacterium spp have been found.143 Therapeutic methods that target microbiota are being explored, such as fecal microbiota transplantation and probiotics (individual probiotics or cocktails). Studies have found that some species are beneficial responses to immunotherapy. Administration of particular probiotic strains (for instance Bifidobacterium) has been revealed to improve the efficiency of immunotherapy via enhancement of PD-1/PD-L1 or cytotoxic T-lymphocyte antigen-4 blockade.144 Mager et al40 revealed that Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species were able to significantly improve the efficacy of ICIs in mouse models of cancer via the production of the metabolite inosine.40 B. longum KACC 91563 strain was able to modulate the hosts’ immune system via immunoglobulin production as well as acting via the maintenance and improvement in the Th1/Th2 balance.145 Routy et al146 observed that the abundance of Akkermansia muciniphila positively affected the clinical responses to ICIs. In addition, prebiotics such as the administration of soluble fibre including inulin and pectin could improve the activity of anti-PD-1 antibodies in various mouse model.147 Engineered probiotics and phage-targeted depletion of pathogenic bacteria.147,148 have also been used in therapy against CRC. A tumor-colonizing form of E. coli has been engineered to synthesize arginine from ammonia, thus boosting intratumoral L-arginine availability, which is essential for the proper function of cytotoxic T cells.149 However, for the development and clinical application of these methods, it is critical to decipher the specialized roles of gut microbiota in regulating the immune responses in CRCs. The findings will give new opportunities to take advantage of our knowledge on the gut microbiota to prevent cancer, augment therapies and reduce adverse effects of treatment.

Conclusion

We here summarize the effects of GMMs, especially SCFAs, BA, and Trp metabolites on the CRCs and CRC-associated immune cells. SCFAs can inhibit the proliferation of CRC cells, but some of SCFAs also improve immune tolerances to promote development of CRCs. BA metabolites possess carcinogenic nature but some secondary BAs also inhibit the proliferation of CRCs, and importantly induce immune tolerance. Trp metabolites can inhibit CRCs through regulating immune cells. For example, dietary fortification with tributyrin, a butyrate glycerol ester, was shown to arrest the development of CRC in mice, implying that butyrate was an effective anticancer metabolite. UDCA, a secondary BA, produced by Ruminococcus gnavus could protect against the development of CRC. However, some of Trp metabolites also directly and indirectly promote the growth of CRCs. Thus, gut microbiota is not only a friend but also a foe of CRCs.

Gut microbiota also directly and indirectly (via immunosuppressive cells) affect tumor metastasis via regulating the shaping of immune-privileged metastatic niches. Since precise and/or personalized treatments of CRCs, which are focused on the gut microbiota, are likely to target either the key cancer-promoting pathogens or the bioactive components or metabolites, all of the findings will increase more opportunities for clinical applications of gut microbiota.

Authors' Contributions:

Rongcun Yang: study design and writing and reviewing the final manuscript. Wenyue Cheng and Fan Li: figures and writing the primary manuscript.

Conflicts of Interest: The authors disclose no conflicts.

Funding: This work was supported by 10.13039/501100001809 NSFC grants (grant number 82271779 , 91842302 and 91629102 ); The Tianjin Science and Technology Commission (grant number, 18JCZDJC35300 ).

Ethical Statement: The study did not require the approval of an institutional review board.

Reporting Guidelines: Not applicable for this article type.
==== Refs
References

1 Bray F. Ferlay J. Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 2018 394 424 30207593
2 Wong S.H. Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications Nat Rev Gastroenterol Hepatol 16 2019 690 704 31554963
3 Levy M. Kolodziejczyk A.A. Thaiss C.A. Dysbiosis and the immune system Nat Rev Immunol 17 2017 219 232 28260787
4 Scott A.J. Alexander J.L. Merrifield C.A. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis Gut 68 2019 1624 1632 31092590
5 Kong C. Liang L. Liu G. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer Gut 72 2023 1129 1142 35953094
6 Zhao Y. Wang C. Goel A. Role of gut microbiota in epigenetic regulation of colorectal cancer Biochim Biophys Acta Rev Cancer 1875 2021 188490
7 Roberts N.J. Zhang L. Janku F. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses Sci Transl Med 6 2014 249ra111
8 Wang J. Zhu N. Su X. Gut-microbiota-derived metabolites maintain gut and systemic immune homeostasis Cells 12 2023 793 36899929
9 Quail D.F. Joyce J.A. Microenvironmental regulation of tumor progression and metastasis Nat Med 19 2013 1423 1437 24202395
10 Koh A. De Vadder F. Kovatcheva-Datchary P. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites Cell 165 2016 1332 1345 27259147
11 Louis P. Hold G.L. Flint H.J. The gut microbiota, bacterial metabolites and colorectal cancer Nat Rev Microbiol 12 2014 661 672 25198138
12 Rey F.E. Faith J.J. Bain J. Dissecting the in vivo metabolic potential of two human gut acetogens J Biol Chem 285 2010 22082 22090 20444704
13 Reichardt N. Duncan S.H. Young P. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota ISME J 8 2014 1323 1335 24553467
14 Vital M. Howe A.C. Tiedje J.M. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data mBio 5 2014 e00889
15 Scott K.P. Martin J.C. Campbell G. Whole-genome transcription profiling reveals genes up-regulated by growth on fucose in the human gut bacterium “Roseburia inulinivorans” J Bacteriol 188 2006 4340 4349 16740940
16 Lucas L.N. Barrett K. Kerby R.L. Dominant bacterial phyla from the human gut show widespread ability to transform and conjugate bile acids mSystems 2021 e0080521 10.1128/mSystems.00805-21
17 Guzior D.V. Quinn R.A. Review: microbial transformations of human bile acids Microbiome 9 2021 140 34127070
18 Bourgin M. Kriaa A. Mkaouar H. Bile salt hydrolases: at the crossroads of microbiota and human health Microorganisms 9 2021 1122 34067328
19 Xiao Y. Zhao J. Zhang H. Mining genome traits that determine the different gut colonization potential of Lactobacillus and Bifidobacterium species Microb Genom 7 2021 000581
20 Adhikari A.A. Seegar T.C.M. Ficarro S.B. Development of a covalent inhibitor of gut bacterial bile salt hydrolases Nat Chem Biol 16 2020 318 326 32042200
21 Coleman J.P. Hudson L.L. Cloning and characterization of a conjugated bile acid hydrolase gene from Clostridium perfringens Appl Environ Microbiol 61 1995 2514 2520 7618863
22 Gopal-Srivastava R. Hylemon P.B. Purification and characterization of bile salt hydrolase from Clostridium perfringens J Lipid Res 29 1988 1079 1085 2903208
23 Bhagwat A. Annapure U.S. In vitro assessment of metabolic profile of Enterococcus strains of human origin J Genet Eng Biotechnol 17 2019 11 31761970
24 Foley M.H. O'Flaherty S. Allen G. Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization Proc Natl Acad Sci U S A 118 2021 e2017709118
25 Jones B.V. Begley M. Hill C. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome Proc Natl Acad Sci U S A 105 2008 13580 13585 18757757
26 Ridlon J.M. Hylemon P.B. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7alpha-dehydroxylating intestinal bacterium J Lipid Res 53 2012 66 76 22021638
27 Ridlon J.M. Kang D.J. Hylemon P.B. Bile salt biotransformations by human intestinal bacteria J Lipid Res 47 2006 241 259 16299351
28 Sato Y. Atarashi K. Plichta D.R. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians Nature 599 2021 458 464 34325466
29 Paik D. Yao L. Zhang Y. Human gut bacteria produce TauEta17-modulating bile acid metabolites Nature 603 2022 907 912 35296854
30 Lee J.Y. Arai H. Nakamura Y. Contribution of the 7beta-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon J Lipid Res 54 2013 3062 3069 23729502
31 Ferrandi E.E. Bertolesi G.M. Polentini F. In search of sustainable chemical processes: cloning, recombinant expression, and functional characterization of the 7alpha- and 7beta-hydroxysteroid dehydrogenases from Clostridium absonum Appl Microbiol Biotechnol 95 2012 1221 1233 22198717
32 Roager H.M. Licht T.R. Microbial tryptophan catabolites in health and disease Nat Commun 9 2018 3294 30120222
33 Dodd D. Spitzer M.H. Van Treuren W. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites Nature 551 2017 648 652 29168502
34 Lamas B. Richard M.L. Leducq V. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands Nat Med 22 2016 598 605 27158904
35 Russell W.R. Duncan S.H. Scobbie L. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein Mol Nutr Food Res 57 2013 523 535 23349065
36 Wlodarska M. Luo C. Kolde R. Indoleacrylic acid produced by commensal Peptostreptococcus species suppresses inflammation Cell Host Microbe 22 2017 25 37.e6 28704649
37 Cervantes-Barragan L. Chai J.N. Tianero M.D. Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8alphaalpha(+) T cells Science 357 2017 806 810 28775213
38 Smith E.A. Macfarlane G.T. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism J Appl Bacteriol 81 1996 288 302 8810056
39 Vujkovic-Cvijin I. Dunham R.M. Iwai S. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism Sci Transl Med 5 2013 193ra191
40 Mager L.F. Burkhard R. Pett N. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy Science 369 2020 1481 1489 32792462
41 Laue H. Denger K. Cook A.M. Taurine reduction in anaerobic respiration of Bilophila wadsworthia RZATAU Appl Environ Microbiol 63 1997 2016 2021 9143131
42 Sivaprakasam S. Bhutia Y.D. Yang S. Short-chain fatty acid transporters: role in colonic homeostasis Compr Physiol 8 2017 299 314 29357130
43 Koppenol W.H. Bounds P.L. Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism Nat Rev Cancer 11 2011 325 337 21508971
44 Astbury S.M. Corfe B.M. Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature Curr Drug Metab 13 2012 815 821 22571479
45 Eslami M. Sadrifar S. Karbalaei M. Importance of the microbiota inhibitory mechanism on the Warburg effect in colorectal cancer cells J Gastrointest Cancer 51 2020 738 747 31735976
46 Chen D. Jin D. Huang S. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota Cancer Lett 469 2020 456 467 31734354
47 Donohoe D.R. Collins L.B. Wali A. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation Mol Cell 48 2012 612 626 23063526
48 Zagato E. Pozzi C. Bertocchi A. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth Nat Microbiol 5 2020 511 524 31988379
49 Bian Z. Sun X. Liu L. Sodium butyrate induces CRC cell ferroptosis via the CD44/slc7a11 pathway and exhibits a synergistic therapeutic effect with erastin Cancers (Basel) 15 2023 423 36672372
50 Yang N. Lan T. Han Y. Tributyrin alleviates gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated mice PLoS One 18 2023 e0289364
51 Xiaohua L.I. Zhihang D. Jianjun Y. Bornyl acetate extracted from Sharen inhibits proliferation, invasion and induces apoptosis by suppressing phosphatidylinositol-3-kinase/protein kinase B signaling in colorectal cancer J Tradit Chin Med 43 2023 1081 1091 37946470
52 Loftfield E. Falk R.T. Sampson J.N. Prospective associations of circulating bile acids and short-chain fatty acids with incident colorectal cancer JNCI Cancer Spectr 6 2022 pkac027
53 Ridlon J.M. Bajaj J.S. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics Acta Pharm Sin B 5 2015 99 105 26579434
54 Ridlon J.M. Harris S.C. Bhowmik S. Consequences of bile salt biotransformations by intestinal bacteria Gut Microb 7 2016 22 39
55 Zhang H. Xu H. Zhang C. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis Cell Death Discov 7 2021 207 34365464
56 Jaye K. Li C.G. Chang D. The role of key gut microbial metabolites in the development and treatment of cancer Gut Microb 14 2022 2038865
57 Sun X.Z. Zhao D.Y. Zhou Y.C. Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer World J Gastroenterol 26 2020 7173 7190 33362375
58 Papadimitriou N. Gunter M.J. Murphy N. Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies Int J Cancer 149 2021 1659 1669 34196970
59 Walczak K. Turski W.A. Rajtar G. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways Amino Acids 46 2014 2393 2401 25012123
60 Liu J. Hong S. Yang J. Targeting purine metabolism in ovarian cancer J Ovarian Res 15 2022 93 35964092
61 Kasimsetty S.G. Bialonska D. Reddy M.K. Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells J Agric Food Chem 57 2009 10636 10644 19919114
62 Vacante M. Ciuni R. Basile F. Gut microbiota and colorectal cancer development: a closer look to the adenoma-carcinoma sequence Biomedicines 8 2020 489 33182693
63 Wu S. Rhee K.J. Albesiano E. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses Nat Med 15 2009 1016 1022 19701202
64 Arthur J.C. Perez-Chanona E. Muhlbauer M. Intestinal inflammation targets cancer-inducing activity of the microbiota Science 338 2012 120 123 22903521
65 Yang J. Wei H. Zhou Y. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites Gastroenterology 162 2022 135 149.e2 34461052
66 Bai X. Wei H. Liu W. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites Gut 71 2022 2439 2450 35387878
67 Ocvirk S. O'Keefe S.J.D. Dietary fat, bile acid metabolism and colorectal cancer Semin Cancer Biol 73 2021 347 355 33069873
68 Fatima S. Hu X. Huang C. High-fat diet feeding and palmitic acid increase CRC growth in beta2AR-dependent manner Cell Death Dis 10 2019 711 31558710
69 Bernstein H. Bernstein C. Payne C.M. Bile acids as endogenous etiologic agents in gastrointestinal cancer World J Gastroenterol 15 2009 3329 3340 19610133
70 Liu D. Liang C.H. Huang B. Tryptophan metabolism acts as a new anti-ferroptotic pathway to mediate tumor growth Adv Sci 10 2023 e2204006
71 Tintelnot J. Xu Y. Lesker T.R. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer Nature 615 2023 168 174 36813961
72 Bender M.J. McPherson A.C. Phelps C.M. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment Cell 186 2023 1846 1862.e26 37028428
73 Jalandra R. Dalal N. Yadav A.K. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer Appl Microbiol Biotechnol 105 2021 7651 7660 34568962
74 O'Keefe S.J. Li J.V. Lahti L. Fat, fibre and cancer risk in African Americans and rural Africans Nat Commun 6 2015 6342 25919227
75 Zheng Z. Wieder T. Mauerer B. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment Int J Mol Sci 24 2023 11673
76 Haghikia A. Jorg S. Duscha A. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine Immunity 44 2016 951 953 27096322
77 Smith P.M. Howitt M.R. Panikov N. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis Science 341 2013 569 573 23828891
78 Yazdandoust E. Hajifathali A. Roshandel E. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation Transpl Immunol 78 2023 101836
79 McBride D.A. Dorn N.C. Yao M. Short-chain fatty acid-mediated epigenetic modulation of inflammatory T cells in vitro Drug Deliv Transl Res 13 2023 1912 1924 36566262
80 Chung D.J. Rossi M. Romano E. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells Blood 114 2009 555 563 19465693
81 Yao Y. Cai X. Zheng Y. Short-chain fatty acids regulate B cells differentiation via the FFA2 receptor to alleviate rheumatoid arthritis Br J Pharmacol 179 2022 4315 4329 35393660
82 Kibbie J.J. Dillon S.M. Thompson T.A. Butyrate directly decreases human gut lamina propria CD4 T cell function through histone deacetylase (HDAC) inhibition and GPR43 signaling Immunobiology 226 2021 152126
83 Shi Y. Su W. Zhang L. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation Front Immunol 11 2020 609060
84 Hao H. Cao L. Jiang C. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis Cell Metab 25 2017 856 867.e5 28380377
85 Ding C. Hong Y. Che Y. Bile acid restrained T cell activation explains cholestasis aggravated hepatitis B virus infection FASEB J 36 2022 e22468
86 Zhu C. Boucheron N. Muller A.C. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation J Hepatol 75 2021 1164 1176 34242699
87 Pols T.W.H. Puchner T. Korkmaz H.I. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor PLoS One 12 2017 e0176715
88 Boonstra A. Barrat F.J. Crain C. 1alpha,25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells J Immunol 167 2001 4974 4980 11673504
89 Tanaka A. Sakaguchi S. Regulatory T cells in cancer immunotherapy Cell Res 27 2017 109 118 27995907
90 Li W. Hang S. Fang Y. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1 Cell Host Microbe 29 2021 1366 1377.e9 34416161
91 Hang S. Paik D. Yao L. Bile acid metabolites control T(H)17 and T(reg) cell differentiation Nature 576 2019 143 148 31776512
92 Xiao R. Lei K. Kuok H. Synthesis and identification of lithocholic acid 3-sulfate as RORgammat ligand to inhibit Th17 cell differentiation J Leukoc Biol 112 2022 835 843 35188700
93 Lv L. Chen Z. Bai W. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance Life Sci 318 2023 121501
94 Chang S. Kim Y.H. Kim Y.J. Taurodeoxycholate increases the number of myeloid-derived suppressor cells that ameliorate sepsis in mice Front Immunol 9 2018 1984 30279688
95 Veglia F. Sanseviero E. Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity Nat Rev Immunol 21 2021 485 498 33526920
96 Galeano N.J.L. Wu H. LaCourse K.D. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer Nature 611 2022 810 817 36385528
97 Rankin L.C. Kaiser K.A. de Los Santos-Alexis K. Dietary tryptophan deficiency promotes gut RORgammat(+) Treg cells at the expense of Gata3(+) Treg cells and alters commensal microbiota metabolism Cell Rep 42 2023 112135
98 Huang T. Cheng L. Jiang Y. Indole-3-pyruvic acid alleviates rheumatoid arthritis via the aryl hydrocarbon receptor pathway Ann Transl Med 11 2023 213 37007545
99 Mascanfroni I.D. Takenaka M.C. Yeste A. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha Nat Med 21 2015 638 646 26005855
100 Apetoh L. Quintana F.J. Pot C. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27 Nat Immunol 11 2010 854 861 20676095
101 Piper C.J.M. Rosser E.C. Oleinika K. Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells Cell Rep 29 2019 1878 1892.e7 31722204
102 Su X. Zhang M. Qi H. Gut microbiota-derived metabolite 3-idoleacetic acid together with LPS induces IL-35(+) B cell generation Microbiome 10 2022 13 35074011
103 de Araujo E.F. Feriotti C. Galdino N.A.L. The Ido-AhR Axis controls Th17/treg immunity in a pulmonary model of fungal infection Front Immunol 8 2017 880 28791025
104 Opitz C.A. Litzenburger U.M. Sahm F. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 478 2011 197 203 21976023
105 Bessede A. Gargaro M. Pallotta M.T. Aryl hydrocarbon receptor control of a disease tolerance defence pathway Nature 511 2014 184 190 24930766
106 Mezrich J.D. Fechner J.H. Zhang X. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells J Immunol 185 2010 3190 3198 20720200
107 Goettel J.A. Gandhi R. Kenison J.E. AHR activation is protective against colitis driven by T cells in humanized mice Cell Rep 17 2016 1318 1329 27783946
108 Tashita C. Hoshi M. Hirata A. Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice World J Gastroenterol 26 2020 918 932 32206003
109 Gargaro M. Vacca C. Massari S. Engagement of nuclear coactivator 7 by 3-hydroxyanthranilic acid enhances activation of aryl hydrocarbon receptor in immunoregulatory dendritic cells Front Immunol 10 2019 1973 31481962
110 Han J.X. Tao Z.H. Wang J.L. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer Nat Microbiol 8 2023 919 933 37069401
111 Hezaveh K. Shinde R.S. Klotgen A. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity Immunity 55 2022 324 340.e8 35139353
112 Frankel T.L. Pasca di Magliano M. Immune sensing of microbial metabolites: action at the tumor Immunity 55 2022 192 194 35139348
113 Campesato L.F. Budhu S. Tchaicha J. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine Nat Commun 11 2020 4011 32782249
114 Fallarino F. Grohmann U. Vacca C. T cell apoptosis by tryptophan catabolism Cell Death Differ 9 2002 1069 1077 12232795
115 Song H. Park H. Kim Y.S. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species Int Immunopharmacol 11 2011 932 938 21352963
116 Ma M. Wang Y. Fan S. Urolithin A alleviates colitis in mice by improving gut microbiota dysbiosis, modulating microbial tryptophan metabolism, and triggering AhR activation J Agric Food Chem 71 2023 7710 7722 37167350
117 Chen H. Tong T. Lu S.Y. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis Cell Metab 35 2023 651 666.e7 36963394
118 Al-Qadami G.H. Secombe K.R. Subramaniam C.B. Gut microbiota-derived short-chain fatty acids: impact on cancer treatment response and toxicities Microorganisms 10 2022 2048 36296324
119 He Y. Fu L. Li Y. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity Cell Metab 33 2021 988 1000.e7 33761313
120 Liu J. Wei Y. Jia W. Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization Redox Biol 56 2022 102452
121 Sivan A. Corrales L. Hubert N. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 350 2015 1084 1089 26541606
122 Gopalakrishnan V. Spencer C.N. Nezi L. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients Science 359 2018 97 103 29097493
123 Deng H. Li Z. Tan Y. A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages Sci Rep 6 2016 29401
124 Cui W. Wang Z. Lv J. MDSCs: the key players in the formation of pre-metastatic niche Front Biosci (Landmark Ed) 28 2023 58 37005751
125 Long X. Wong C.C. Tong L. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity Nat Microbiol 4 2019 2319 2330 31501538
126 Wu J. Dong W. Pan Y. Crosstalk between gut microbiota and metastasis in colorectal cancer: implication of neutrophil extracellular traps Front Immunol 14 2023 1296783
127 Li R. Zhou R. Wang H. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer Cell Death Differ 26 2019 2447 2463 30850734
128 Kim Y. Lee E.J. Jang H.K. Statin pretreatment inhibits the lipopolysaccharide-induced epithelial-mesenchymal transition via the downregulation of toll-like receptor 4 and nuclear factor-kappaB in human biliary epithelial cells J Gastroenterol Hepatol 31 2016 1220 1228 26574150
129 Zhang K. Dong Y. Li M. Clostridium butyricum inhibits epithelial-mesenchymal transition of intestinal carcinogenesis through downregulating METTL3 Cancer Sci 114 2023 3114 3127 37243376
130 Yao L. Jiang L. Zhang F. Acetate promotes SNAI1 expression by ACSS2-mediated histone acetylation under glucose limitation in renal cell carcinoma cell Biosci Rep 40 2020 BSR20200382
131 Song X. An Y. Chen D. Microbial metabolite deoxycholic acid promotes vasculogenic mimicry formation in intestinal carcinogenesis Cancer Sci 113 2022 459 477 34811848
132 Zhu Y. Zhu M. Lance P. Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells Biochem Biophys Res Commun 425 2012 607 612 22885178
133 Baek M.K. Park J.S. Park J.H. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells Cancer Lett 290 2010 123 128 19782465
134 Rossi T. Vergara D. Fanini F. Microbiota-derived metabolites in tumor progression and metastasis Int J Mol Sci 21 2020 5786 32806665
135 Park G.Y. Han Y.K. Han J.Y. Tauroursodeoxycholic acid reduces the invasion of MDA-MB-231 cells by modulating matrix metalloproteinases 7 and 13 Oncol Lett 12 2016 2227 2231 27602168
136 Duan Z. Li Y. Li L. Promoting epithelial-to-mesenchymal transition by D-kynurenine via activating aryl hydrocarbon receptor Mol Cell Biochem 448 2018 165 173 29442266
137 Wu K.K. Cytoguardin: a tryptophan metabolite against cancer growth and metastasis Int J Mol Sci 22 2021 4490 33925793
138 Walczak K. Langner E. Szalast K. A tryptophan metabolite, 8-hydroxyquinaldic acid, exerts antiproliferative and anti-migratory effects on colorectal cancer cells Molecules 25 2020 1655 32260268
139 DeStefano Shields C.E. White J.R. Chung L. Bacterial-driven inflammation and mutant BRAF expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy Cancer Discov 11 2021 1792 1807 33632774
140 Brennan C.A. Clay S.L. Lavoie S.L. Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression Gut Microb 13 2021 1987780
141 Kim M.H. Kang S.G. Park J.H. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice Gastroenterology 145 2013 396 406.e1-10 23665276
142 Duboc H. Rajca S. Rainteau D. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases Gut 62 2013 531 539 22993202
143 Matson V. Fessler J. Bao R. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients Science 359 2018 104 108 29302014
144 Kazmierczak-Siedlecka K. Roviello G. Catalano M. Gut microbiota modulation in the context of immune-related aspects of Lactobacillus spp. and Bifidobacterium spp. in gastrointestinal cancers Nutrients 13 2021 2674 34444834
145 Choi M. Lee Y. Lee N.K. Immunomodulatory effects by Bifidobacterium longum KACC 91563 in mouse splenocytes and macrophages J Microbiol Biotechnol 29 2019 1739 1744 31546293
146 Routy B. Le Chatelier E. Derosa L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 359 2018 91 97 29097494
147 Wong C.C. Yu J. Gut microbiota in colorectal cancer development and therapy Nat Rev Clin Oncol 20 2023 429 452 37169888
148 Fazzino L. Anisman J. Chacon J.M. Phage cocktail strategies for the suppression of a pathogen in a cross-feeding coculture Microb Biotechnol 13 2020 1997 2007 32814365
149 Canale F.P. Basso C. Antonini G. Metabolic modulation of tumours with engineered bacteria for immunotherapy Nature 598 2021 662 666 34616044
